Ligand Pharmaceuticals Raises 2026 Adjusted EPS Outlook After Q3 Beat

The company lifted its adjusted earnings per diluted share range to about $9.50 to $9.75 while keeping its $270 million to $310 million revenue forecast unchanged.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.